M. Tanen

发表

A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging

P. Scheltens, G. Bråthen, S. Sando, 2017, Alzheimer's & dementia.

Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization.

S. O’Rahilly, J. Berger, D. Moller, 2002, Endocrinology.

The novel BACE inhibitor MK-8931 dramatically lowers CSF beta-amyloid in patients with mild-to-moderate Alzheimer's disease

M. Forman, L. Ereshefsky, O. Laterza, 2013, Alzheimer's & Dementia.

Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.

A. Simon, W. Potter, A. Smith, 2015, Journal of Alzheimer's disease : JAD.

Kinetics of TH2 biomarkers in sputum of asthmatics following inhaled allergen

R. Mogg, Z. Diamant, I. Kamerling, 2015, European clinical respiratory journal.

Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta -hydroxysteroid dehydrogenase type 1 expression and activity.

R. Thieringer, J. Berger, D. Moller, 2001, The Journal of biological chemistry.

Combining processing methods & sensitive detection techniques for biomarker analysis: a feasibility study

Z. Diamant, A. Cohen, M. Tanen, 2009 .

Nonspecific binding of Aβ42 to polypropylene tubes and the effect of Tween-20.

O. Laterza, Wesley K. Tanaka, A. Dallob, 2010, Clinica chimica acta; international journal of clinical chemistry.

Analysis of the functional role of steroid receptor coactivator-1 in ligand-induced transactivation by thyroid hormone receptor.

M. Tanen, M. Bagchi, M. Jeyakumar, 1997, Molecular endocrinology.

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double‐blind, placebo‐controlled studies with single oral doses

W. Zeng, G. Herman, A. Bergman, 2005, Clinical pharmacology and therapeutics.

Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator.

Bruce A. Johnson, J. Berger, D. Moller, 2003, Molecular endocrinology.

Peroxisome Proliferator-activated Receptor-γ Ligands Inhibit Adipocyte 11β-Hydroxysteroid Dehydrogenase Type 1 Expression and Activity*

R. Thieringer, J. Berger, D. Moller, 2001, The Journal of Biological Chemistry.

Novel Peroxisome Proliferator-activated Receptor (PPAR) γ and PPARδ Ligands Produce Distinct Biological Effects*

Margaret S. Wu, Y. Li, M. D. Leibowitz, 1999, The Journal of Biological Chemistry.

Induction of Adipocyte Complement-related Protein of 30 Kilodaltons by Ppar␥ Agonists: a Potential Mechanism of Insulin Sensitization

S. O’Rahilly, J. Berger, D. Moller, 2022 .

Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.

J. Holst, W. Zeng, C. Deacon, 2006, The Journal of clinical endocrinology and metabolism.

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients

Michael Tanen, Matthew E. Kennedy, Wei Li, 2016, Science Translational Medicine.

Dipeptidyl Peptidase‐4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP‐1

J. Holst, B. Weiss, N. Thornberry, 2010, Clinical pharmacology and therapeutics.

Pharmacokinetics and Pharmacodynamics of the BACE1 Inhibitor Verubecestat (MK‐8931) in Healthy Japanese Adults: A Randomized, Placebo‐Controlled Study

Michael Tanen, M. Forman, M. Vugt, 2019, Clinical pharmacology and therapeutics.

Pharmacokinetics and Pharmacodynamic Effects of the Oral DPP‐4 Inhibitor Sitagliptin in Middle‐Aged Obese Subjects

W. Zeng, G. Herman, A. Bergman, 2006, Journal of clinical pharmacology.

Transcriptional silencing by unliganded thyroid hormone receptor beta requires a soluble corepressor that interacts with the ligand-binding domain of the receptor

G. Tong, M. Tanen, M. Bagchi, 1996, Molecular and cellular biology.

Ligand Modulates the Interaction of Thyroid Hormone Receptor with the Basal Transcription Machinery (*)

G. Tong, M. Tanen, M. Bagchi, 1995, The Journal of Biological Chemistry.

Evaluation of Urinary Renal Biomarkers for Early Prediction of Acute Kidney Injury Following Partial Nephrectomy: A Feasibility Study.

B. Lane, W. Boshoven, Pamela Grady, 2020, European urology focus.

Quantification of tau in cerebrospinal fluid by immunoaffinity enrichment and tandem mass spectrometry.

Michael E. Lassman, Daniel S Spellman, O. Laterza, 2014, Clinical chemistry.

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.

W. Zeng, G. Herman, A. Bergman, 2006, Clinical therapeutics.

Localization of PPARδ in murine central nervous system: expression in oligodendrocytes and neurons

C. Austin, J. Berger, D. Moller, 2003, Brain Research.

Next Generation Ligand Binding Assays—Review of Emerging Real-Time Measurement Technologies

S. Fraser, M. Schwickart, M. Tanen, 2014, AAPS Journal.

Consistency of BACE inhibitor-mediated brain amyloid production inhibition by MK-8931 in Alzheimer’s disease patients and healthy young adults

M. Forman, J. Palcza, J. Stone, 2013, Alzheimer's & Dementia.

The novel BACE inhibitor MK-8931 dramatically lowers cerebrospinal fluid Aβ peptides in healthy subjects following single- and multiple-dose administration

M. Forman, L. Ereshefsky, O. Laterza, 2012, Alzheimer's & Dementia.

High-throughput simultaneous analysis of RNA, protein, and lipid biomarkers in heterogeneous tissue samples.

Jason J. Z. Liao, M. Marton, Peggy H. Wong, 2011, Clinical chemistry.

Induction of Adipocyte Complement-Related Protein of 30 Kilodaltons by PPARγ Agonists: A Potential Mechanism of Insulin Sensitization.

S. O’Rahilly, J. Berger, D. Moller, 2002, Endocrinology.

Peroxisome Proliferator-activated Receptor- g Ligands Inhibit Adipocyte 11 b -Hydroxysteroid Dehydrogenase Type 1 Expression and Activity*

R. Thieringer, J. Berger, D. Moller, 2001 .

Analysis of the functional role of steroid receptor coactivator-1 in ligand-induced transactivation by thyroid hormone receptor.

M. Tanen, M. Bagchi, M. Jeyakumar, 1997, Molecular Endocrinology.